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S u m m a r y intercellular adhesion molecule (ICAM)-3 is a recently described member of the immunoglobulin
superfamily and, as such, is closely related to ICAM-1 and fCAM-2. All three [CAMS are cognate for
the counter-receptor lymphocyte function associated antigen-1 (LFA-1. CDlla/CD18). Unlike
lCAM-1 and lCAM-2. ICAM-3 is constitutivcly expressed at high levels on resting leucocytes. We
investigated the expression and function of ICAM-3 in normal skin (n^5). as well as its expression in
psoriasis (fj=4), atopic eczema (n^4), allergic (rhus) contact dermatitis (n^3), and cutaneous T-cell
lymphoma (CTCL, (1^2).
Five-micrometre cryostat sections of skin were stained using monoclonal antibodies to ICAM-3
and a well characterized immunoperoxidase technique. In normal skin, ICAM-3 was expressed by all
cutaneous leucocytes but most striking was the strong expression of ICAM-3 by Langerhans cells
within both epidermis and dermis. This observation was confirmed by double-labelling with CDla
and negative staining with an IgGl isotype control. In psoriasis, atopic eczema, allergic contact
dermatitis, and CTCL, ICAM-3 was co-expressed on all CDla^ cells, although, in psoriasis, the
intensity of ICAM-3 expression was reduced. Functional blocking experiments were performed to
determine whether the observed ICAM-3 expression on Langerhans cells was functionally important
in antigen presentation, CD4^ T cells were prepared from peripheral blood and lO'' CD4* T cells
combined with i C epidermal cells harvested from keratome biopsies of normal skin of an individual
allogeneic to the T-cell donor. Addition of SO fig anti-ICAM-3 to the co-culture resulted in a
consistent (50%) reduction in degree of alloantigen presentation by Langerhans cells lo T cells.
Inhibition was 77% of that produced by the addition of anti-LFA-1.
These data indicate that ICAM-3 is constitutively expressed by Langerhans cells and is a major
ligand for LFA-1 on CD4+ T cells during their response to Langerhans cells. Because fresh
Langerhans ceils constitutively express little ICAM-1, whereas ICAM-3 is constitutively expressed
at high levels, it would appear that lCAM-3 is the dominant functional ICAM on in situ Langerhans
cells in the normal epidermis.
Three immunoglobulin superfamily members, intercel-
lular adhesion molecules (ICAM)-l, ICAM-2 and ICAM-
?, in conjunction with their ligand lymphocyte func-
tion-associated antigen-1 (LFA-1. CI)lla/CD18) are
important facilitators of adhesion events in inflamma-
tion.' ^ ICAM-1, ICAM-2 and ICAM-3 are membrane
glycoproteins whose structure and immunobiology are
well characterized.""^ ICAM-1 has live immunoglobu-
lin-Iikc domains** whereas ICAM-2 contains only two
such domains: however, these have ib% sequence
homology to the tirst two domains of ICAM-1.' The
most recently identified member ofthe [CAM family is a
124.000 molecular weight glycosylated glycoprotein.
ICAM-3, ~ " that contains five immunoglobulin-like
domains — the first two of which share 37% sequence
homology with those of ICAM-2^'''- Although ICAM-3
is structurally similar to the other two ICAMs it differs
from them in that it is constitutively expressed on
resting lymphocytes and monocytes thereby implying
potential importance in lymphocyte activation."* "
The distribution of ICAM-1 in normal and diseased
skin is well characterized.'"*""* ICAM-l is constitutively
expressed by dermal endothelial celis and is inducible on
keratinocytes by gamma interferon.'"* tumour necrosis
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'^ and by a variety of non-cytokines including
phorbol ester.''^ urushiol.''^ and all-trans retinoic
"̂̂ . ICAM-l/LFA-1 interactions are instrumental
in cutaneous leucocyte trafficking, keratinocyte/Ieuco-
cyte adhesion, and antigen presentation by Langerhans
cells. In contrast, in normal skin. ICAM-2 is probably
expressed solely by endothelium and appears not to be
inducibic on other cellular components ofthe epidermis
or dermis. The distribution and function of lCAM-3 in
normal and inflamed skin is poorly elucidated at
present."" Using anti-ICAM-3 monoclonal antibodies
we have investigated: (i) the expression of ICAM-3 in
normal skin and inflammatory dermatoses. and (ii) the
functional role of ICAM- 3 as a costimulatory molecule
in Langerhans cell/T-cell interactions.
Methods
Patients
Four mm skin biopsies were procured under 1% plain
lignocaine anaesthesia from five normal volunteers and
from the untreated involved skin of chronic plaque
psoriasis |n — 4). atopic eczema (n — 4), allergic (rhus)
contact dermatitis: a 48-h patch test to poison ivy/
poison oak mix 1:50 (w/v) in alcohol (HoUister Stier.
Elkhart. IN. U.S.A.: n = 3) and plaque stage cutaneous
T-cell lymphoma (CTCL. n — 2). No patients were
receiving systemic therapy for their disease at time of
biopsy. All biopsies were orientated in optima! cutting
temperature embedding medium (OCT. Miles Labora-
tories. Elkhart. IN. U.S.A.). snap frozen in liquid nitro-
gen, and stored at —7iy^C until use.
For proliferation assay studies, keratome biopsies
were taken from normal buttock skin under local 1%
plain lignocaine anaesthesia. Biopsies were taken using
a Castro Viejo keratome set at 0-2 mm so that the
majority of the biopsy was composed of epidennis.
The procurement of biopsies was performed under
approval of the University of Michigan Medical Center
Institutional Review Board.
Immunohistology
Five-micrometre cryostat sections were stained using
monoclonal antibodies to ICAM-3 (ICRl and ICR8:
ICOS Corporation. Bothell. WA, U.S.A.) and a well-
characterized immunoperoxidase technique (Vecta-
stain ABC kit. Vector Laboratories. Burlingame. CA.
U.S.A.): 3-amino-9-ethyl carbazole was used as the
chromogen and the sections were counterstained with
1% haematoxylin. Substitution ofthe primary antibody
with an IgGi isotype control, and omission of the
primary antibody, served as negative controls.
To ascertain whether ICAM-3 expression was loca-
lized to Langerhans cells, a double-labelling technique
was used. Antibody ICRl was used to identify ICAM-3
and Leu 6 (Becton Dickinson, Burlingame, California.
U.S.A.) labelled CDla' Langerhans cells. The tirst anti-
body was visualized with the avidin-biotin immuno-
peroxidase technique using 3.3'-diaminobenzidine as
the chromogen and the second antibody was visualized
using an alkaline phosphatase/anti-alkaline phos-
phatase technique, with fast blue as chromogen. as
previously described.~
Epidermal proliferation assay
Epidermal cell preparation. Keratome biopsies were tryp-
sinized overnight at 4"C in 10 m! of Dulbecco's phos-
phate-buffered saline (PBS) containing dispase
(Collaborative Research. Becton Dickinson Labware.
Bedford. MA. U.S.A.). The epidermis was then sepa-
rated from the dermis and transferred to 0 2S% trypsin
for 20 min at 37 C. Fetal bovine serum (FBS) containing
0-01% DNAse was added to stop trypsinization and the
epidermis was dispersed into a single cell suspension
before filtering through a 112/im nylon mesh. Epider-
mal cells were adjusted to a concentration of 1 x 10^
cells/ml of RPMI (Whittaker Bioproducts inc. Walkers-
ville. MA. U.S.A.) and 10% FBS.
Monomidear cell preparation, Heparinized peripheral
blood was obtained from normal volunteers and mono-
nuclear cells (MNC) isolated. Blood was diluted 1:1 with
PBS and layered on to Ficoll-Hypaque (Sigma Chemical
Co. St Louis. MO. U.S.A.) and centrifuged at 1 500 r.p.m.
for 35 min at 20 C without braking. The MNC were
harvested, washed three times in PBS plus lOTo FBS.
and adhered to plastic flasks for 1 h at 37X\ All non-
adherent cells were collected as peripheral blood lym-
phocytes (PBL).
Preparation of CD4'^ T cells. Purified CD4+ T cells were
obtained by treating PBL with the following monoclonal
antibody cocktail: anti-CD8 (0KT8. ATCC. Rockville.
MD. U.S.A.). anti-HLA-DR (HBS5. ATCC). and anti-
CDllb (OKMl. ATCC). Antibodies were diluted 1:50
using RPMI and 1% FBS. One ml of the antibody
cocktail was added to 20 x 10^ PBL in a 15 ml round-
bottom, polypropylene tube (Falcon. Lincoln Park. Nl.
U.S.A.) and incubated at 4 C for 45 min with agitation
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every 1 5 min. and then wasiied tiiree times witii PBS
and ]%FBS.
Goat antimouse IgG-conjugated magnetic beads
(Dynabeads. M-45(). DynaJ. Great Neck. NY. U.S.A.)
were washed twice with PBS and 10% FBS. resuspended
in RPMI 1640 plus 1% FBS, and added at a concentra-
tion of 3 (beads)/! PBL. Tbe PBL-bead mixture was
incubated for 4Smin at 4 C witii reguiar (Smin)
agitation. The solution was then diluted to 10 mi with
PBS pius \{)% FBS. and incubated for a furtiier 1S tnin
at 4 C. again with Smin agitation. B celis. monocytes,
naturai kiiier ceils, atid Ci)8+ T cells were removed from
the PBL suspension by applying the tube containing them
to a magnet for 3- S min. drawing tiie bead-attached celis
to tbe tube wall, and thus allowing the unbound celis to be
removed in the supernatant. Tiie removed supernatant
was centrifuged at 1400 r.p.m. at 4 C for 8 min. Tbe
viability of CD4 ^ -enriched cells present in tbe superna-
tant was assessed using trypan blue.
T-cell proUjeration assaij. To eacb well of a 96-weii.
round-bottom microfilter plate (Costar. Cambridge.
MA. U.S.A.) was added SO//i of puriiied CD4+ T cells
(lO"" cells) andlO' epidermal cells. Various experiments
were performed in triplicate with addition of eitiier
50/ig anti-ICAM-3 (ICR8). 50^g IgGl isotype con-
troi. or SO//g anti LFA-1 (CDlla/i8). Tbe cultures
were incubated at 37 C ibr 6 days before pulsing witb
0-0 3 7 MBq per weil of triated thymidine. harvested 18 h
later, and counted in a liquid scintiilation counter. Tbe
mean ± standard error of tiie mean (SEM) count per




Bolii antibodies to iCAM-3 (ICRl and ICR8) showed
equivalent staining in normai and diseased skin. In
normal sicin. tiie predominant, constitutive staining
was of epidermai Langerhans ceils (Fig. 1) as confirmed
by doubie-labeiling witb CDla (Fig. 2). Staining with
IgGl isotype controi was negative. Other cell types that
stained were predominantiy of ieucocyte iineage but
neitiier keratinocytes. fibroblasts nor endotheliai ceiis
expressed lCAM-3.
Psoriasis, atopic eczema, ailergic contact dermatitis,
and CTCL aiso demonstrated positive leucocyte staining
for ICAM-3 (Figs 3-6). again with expression by
Langerhans ceiis. confirmed by doubie-Iabelling (Fig.
4) in both epidermis and dermis. iCAM-3 expression by
psoriatic epidermai Langerhans ceils was fainter than
tiiat observed in either normal skin or tbe other
dermatoses studied {Fig.. 3). In none of the four inflam-
matory dermatoses studied was ICAM-3 expressed on
keratinocytes, tibroblasts or endotheiial ceiis (Eigs 3-6).
Proliferation assay
Combining aiiogeneic epidermai celis to antigen-
presenting cell-depieted CD4^ T celis resuited in T-ceii
proliferation tbat was not significantiy iniiibited by the
addition oflgGl. isotype control imtnunoglobuiin (Fig.
7). Addition of ICR8 (IgGl antibody to ICAM-3) to the
epidermai ceii+CD4^ T-cell cuiture resuited in a
50 ±14% reduction in alloantigen presentation, as
Figure 1. Immunoperoxidase staining of
normal skin witb anti-K'AM-J. Dendriltc
epidermal l,ant;t'rhans cells are strongly
positive for lCAM-J (x25t)).
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Figure 2. Double-labelling of normal
epidermis with anti-ICAM-i Ibrownl and
anti CDla (blue). Note concurrence of
ICAM-S and CDla (black staining) on
epidermal Langerhans cells indicating
constitutive expression of ICAM- i (x 1()()|.
measured by T-cell proliferation. Inhibition of T-cell
proliferation by addition of anti-LFA-1 was 65 ± 5%.
Thus. anti-lCAM-3 inhibited T-cell proliferation t(i
about 77% of that observed with anti-LFA-1, n= :>
(Fig. 7).
Discussion
In this study we have demonstrated that ICAM-3 is
constitutively and strongly expressed by Langerhanii
cells in situ in the epidermis of normal skin. ICAM-:1
expression is not limited to normal skin as it is also
observed on dermal and epidermal Langerhans cells and
cutaneous leucocytes in psoriasis, atopic eczema, aller-
gic contact dermatitis and CTCL. The reduced ICAM-:!
expression on epidermal Langerhans cells in psoriatic
skin is not readily explicable, although it is in agreement
with observations that similar reductions in CDla and
FKC/3 occur in psoriasis.^" Furthermore, the presence of
ICAM-3 on epidermal Langerhans cells appears to be
integral for alloantigen presentation to CD4"̂  T cells and
their subsequent proliferative response.
Previous investigations of ICAM-1 and ICAM-2
expression in normal skin,''*"^^ have demonstrated
constitutive expression limited to endothelium.
Langerhans cells do not express ICAM-2 and their
constitutive epidermal and dermal expression of
ICAM-1 is minimal.'"^ demonstrable only by highly
sensitive immunoelectron microscopy techniques.
Prior studies have demonstrated strong expression of
ICAM-3 on epidermal Langerhans cells in normal
skin."" although ICAM-3 distribution in inilammatory
•i.
Figure 3. Immunoperoxidase staining of
involved psoriatic skin with anti-lCAM-5.
Epidermal Langerhans cells and dermal
leucocytes are positive for ICAM-J ( xlOO).
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l-'igure 4. Double-lahelling of involved
psoriatic skin with anti-ICAM-3 (brown)
and anti-CDla (blue). Note concurrence of
ICAM-J and CUla (black staining! on
Langerhans cells. ICAM-3 positive
leucocytes within the epidermis stain
brown (xlOO).
dermaloses has not been examined. ICAM-3 is not.
however, unique to cutaneous cells as it has been
described on cells of leucocyte lineage in a variety of
organs including lymph node, spleen, liver, kidney. lung
and rheumatoid synovium.""* Furthermore. ICAM-3 has
rarely been observed on endothelium. although there is
one report of its presence on endothelial ceils in lym-
phomas."
The observation that ICAM- 3 is strongly and consti-
tutively expressed by Langerhans cells in situ in normal
epidermis indicates that this adhesion molecule is
important in initial antigen presentation to T cells.
Both ICAM-1 and ICAM-2 are costimulatory when
ligated to LFA-l,̂ *"'̂ ^ and ICAM-1 is costimulatory for
activated T cells.^'^^ By contrast ICAM-3 is costimula-
tory for both resting as well as activated T cells'' and
this may he a consequence of its high constitutive
expression. In vivo, Langerhans cell expression of
ICAM-1 is very low. although in vitro culture condi-
tions significantly enhance ICAM-1 expression and
such enhancement is concurrent with increased
potency of antigen presentation. '' " Blocking anti-
body to ICAM-3 significantly abrogates alloantigen
presentation and subsequent T-cell proliferation and
this observation underscores the importance of ICAM-
3 to Langerhans cell function. ICAM-3 should be added
Figure S. immunoperoxidase staining of
rluis allergic contact dennatitis with anti-
ICAM-3. Epidermal Langerhans cells are
strongly positive for ICAM-3 whereas
inliltrating mononuclear leucocytes are less
positive for ICAM- 3 (x 50).
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Figure 6. Immunoperoxidase staining of
cutaneous T-cell lymphoma with anti-
ICAM-3. Epidermal Langerhans cells and
mononuclear leucocytes ofthe dermal and
epidermal inliltrate arc strongly positive for
ICAM-3 |x50).
to the list of other accessory/costimulatory molecules
such as B7, CTLA-4 ligand A and ICAM-1. present on
cutaneous antigen-presenting cells. Most probably
high, constitutive expression. ofICAM-3 is of particular
value to antigen-presenting cells whose expression of
ICAM-1 is low or absent, i.e. Langerhans cells. Under
such circumstances of low ICAM-1 expression, a strong
costimulatory signal could be generated via ICAM-3
before upregulation and subsequent activity of ICAM-












Figure 7. Percentage inhibition of CD4 * T-cell proliferation by ICAM- 3
and LFA-1 antibodies. Epidermal cell suspension stimulation of CD4'
T-cell proliferation is inhibited by coincubation with antibody to
ICAM-3 and to a slightly greater extent by antibody to LFA-1. By
comparison, an Ig[]l isotype control has litlle effect on T-cell prolif-
eration. 10' T cells were incubated with 10^ epidermal ceils. Bars are
means ± SEM; n = 3.
cell activation occurring in situ during the effector phase
of intracutaneous immune reactions than it is during
primary sensitization in the draining lymph node.
In conclusion. ICAM-3 is probably the dominant
functional ICAM on in situ Langerhans cells and is
likely to be an integral molecule in the initiation of
antigen-driven cutaneous inflammation.
Addendum in proof
while this article was in proof two reports ^'^~ were
published which verify the importance of ICAM-3 as a
costimulatory molecule on Langerhans cells.
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